Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib versus bendamustine + rituximab in previously untreated CLL/SLL
2023-509976-40-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of zanubrutinib, bendamustine, rituximab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival in Cohort 1. Planned start May 2018; status: authorised.
02
Drugs
zanubrutinibbendamustinerituximabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-509976-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509976-40-00.